At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VBIO Valion Bio Inc
Pre-Mkt 09-03 05:03:26 EDT
3.12
+0.05
+1.63%
盘前3.11
-0.01-0.32%
04:00 EDT
High3.24Low2.70Vol149.62K
Open3.02D1 Closing3.07Amplitude17.56%
Mkt Cap2.77MTradable Cap2.76MTotal Shares887.59K
T/O445.85KT/O Rate16.91%Tradable Shares884.65K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Valion Bio Inc: Lisa Wolf Appointed as President & Chief Operating Officer; to Continue to Serve as CFO
THOMSON REUTERS  ·  09-01 20:08
Valion Bio Inc: Lisa Wolf Appointed as President & Chief Operating Officer; to Continue to Serve as CFO
Valion Bio Names CFO Lisa Wolf President, COO After CEO Handley Exits
Reuters  ·  09-01 18:09
Valion Bio Names CFO Lisa Wolf President, COO After CEO Handley Exits
Valion Bio Inc trading halted, news pending
TIPRANKS  ·  08-29
Valion Bio Inc trading halted, news pending
Valion Bio - 1-for-25 Reverse Stock Split, Become Effective on August 31 - SEC Filing
THOMSON REUTERS  ·  08-27
Valion Bio - 1-for-25 Reverse Stock Split, Become Effective on August 31 - SEC Filing
Valion Bio Announces 1-for-25 Reverse Stock Split Effective Aug. 31
Reuters  ·  08-27
Valion Bio Announces 1-for-25 Reverse Stock Split Effective Aug. 31
Valion Bio Amends 8-K to Report Final Vote Tally on Reverse Stock Split Approval
Reuters  ·  08-21
Valion Bio Amends 8-K to Report Final Vote Tally on Reverse Stock Split Approval
Valion Bio Agrees to Sell 1,500 Series B Preferred Shares to 3i for $1.5 Million in Private Placement
Reuters  ·  08-17
Valion Bio Agrees to Sell 1,500 Series B Preferred Shares to 3i for $1.5 Million in Private Placement
Valion Bio - Michael K. Handley Terminated as Chief Executive Officer, Effective August 16 - SEC Filing
THOMSON REUTERS  ·  08-17
Valion Bio - Michael K. Handley Terminated as Chief Executive Officer, Effective August 16 - SEC Filing
Valion Bio Q2 Net Loss Widens to $7.1 Million; Operating Loss Deepens to $6.4 Million
Reuters  ·  08-15
Valion Bio Q2 Net Loss Widens to $7.1 Million; Operating Loss Deepens to $6.4 Million
Ukraine Health Ministry Starts Technical Assessment of Valion Bio’s Entolimod Dossier
Reuters  ·  08-13
Ukraine Health Ministry Starts Technical Assessment of Valion Bio’s Entolimod Dossier
Top Premarket Decliners
MT Newswires Live  ·  08-13
Top Premarket Decliners
Valion Bio Says U.S.-Funded Entolimod Safety Study for Radiation-Induced GI Injury Starts This Week
Reuters  ·  08-12
Valion Bio Says U.S.-Funded Entolimod Safety Study for Radiation-Induced GI Injury Starts This Week
NASDAQ Trade Halt Volatility Trading Pause at 09:35 Am
Reuters  ·  08-12
NASDAQ Trade Halt Volatility Trading Pause at 09:35 Am
Valion Bio Issues 1,287 Series a Preferred Shares in Unregistered Sale Tied to $750,000 Milestone Payment
Reuters  ·  08-07
Valion Bio Issues 1,287 Series a Preferred Shares in Unregistered Sale Tied to $750,000 Milestone Payment
3I, Lp Reports 9.9% Stake in Valion Bio Inc as of July 28 - SEC Filing
THOMSON REUTERS  ·  08-03
3I, Lp Reports 9.9% Stake in Valion Bio Inc as of July 28 - SEC Filing
Ukraine Health Ministry Accepts Valion Bio Entolimod Dossier for Regulatory Review
Reuters  ·  07-22
Ukraine Health Ministry Accepts Valion Bio Entolimod Dossier for Regulatory Review
Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway
THOMSON REUTERS  ·  07-22
Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway
Valion Bio - Formal Review of Entolimod in Ukraine May be Completed in 45 to 60 Days
THOMSON REUTERS  ·  07-22
Valion Bio - Formal Review of Entolimod in Ukraine May be Completed in 45 to 60 Days
Valion Bio Notifies Availability of Press Release on Entolimod Trial at Sheba Medical Center
Reuters  ·  07-21
Valion Bio Notifies Availability of Press Release on Entolimod Trial at Sheba Medical Center
Valion Bio Advances Entolimod Program with Government Engagement, Manufacturing Scale-Up, Oncology Supportive Care Plans
MT Newswires Live  ·  07-14
Valion Bio Advances Entolimod Program with Government Engagement, Manufacturing Scale-Up, Oncology Supportive Care Plans

Introduction

Company Name.
Valion Bio Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
Issue price:
--